And here are the numbers from the drug generating 4 Billion (with a B) for UC.
"Patients treated with adalimumab achieved a significantly higher rate of clinical remission than patients receiving placebo both at Week 8 (17% vs 9%; P=.019) and at Week 52 (17% vs 9%; P=.004).
Certainly makes the B 50% CR numbers look impressive even though they are unblinded, and uncontrolled.